Use of erlotinib throughout pregnancy: A case-report of a patient with metastatic lung adenocarcinoma

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 469-472

  Rivas, Giovanna ^a,b   Llinás, Nestor ^a,b   Bonilla, Carlos ^a,b   Rubiano, Juan ^a,b   Cuello, Javier ^a,b   Arango, Natalia ^a,b  

^a Instituto Nacional de Cancerología   (Colombia)

^b UNIVERSIDAD EL BOSQUE   (Colombia)

Author keywords

EGFR tyrosine kinase inhibitor; Erlotinib; Lung adenocarcinoma; Lung cancer; Metastasis; Non small cell lung carcinoma; Pregnancy; Treatment

Indexed keywords

ERLOTINIB;

ADULT; APGAR SCORE; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CESAREAN SECTION; CONGENITAL MALFORMATION; DYSPNEA; FEMALE; FETUS DEATH; FETUS RISK; FOLLOW UP; GESTATIONAL AGE; GROWTH CURVE; HUMAN; INTRAUTERINE GROWTH RETARDATION; LUNG ADENOCARCINOMA; MEDIASTINUM METASTASIS; OLIGOHYDRAMNIOS; OLIGOMENORRHEA; PREGNANCY; PRIORITY JOURNAL; RADIATION DOSE; STEREOTACTIC RADIOSURGERY; TREATMENT DURATION;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; FEMALE; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM METASTASIS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84863775511     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.03.026     Document Type: Article

References (11)

1. Pavlidis N. Lung cancer during pregnancy: an emerging issue. Lung Cancer 2008, 59(March (3)):279-281.
2. Pavlidis N.A. Coexistence of pregnancy and malignancy. Oncologist 2002, 7(4):279-287. Review. Erratum in: Oncologist 2002;7(4):279-87.
3. Azim H.A., Peccatori F.A., Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer 2010, 67(March (3)):251-256.
4. Zambelli A., Prada G.A., Fregoni V., Ponchio L., Sagrada P., Pavesi L. Erlotinib administration for advanced non-small cell lung cancer during the first 2months of unrecognized pregnancy. Lung Cancer 2008, 60(June (3)):455-457.
5. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(March-April (2)):69-90.
6. Morgensztern D., Waqar S., Subramanian J., Gao F., Govindan R. Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. J Thorac Oncol 2009, 4(December (12)):1524-1529.
7. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, January.
8. Lee H.L., Liam C.K., Pang Y.K., Chua K.T., Lim B.K., Lai N.L. Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure. Lung Cancer 2011, 74(2):349-351.
9. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(August (8)):735-742.
10. Patyna S., Haznedar J., Morris D., Freshwater K., Peng G., Sukbuntherng J., et al. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2009, 86(June (3)):204-213.
11. Wada Y., Ozaki H., Abe N., Nagamitsu T., Ohta H., Nakahara T., et al. Effects of KRN633, an inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, on vascular development of placenta and fetus of mid-pregnancy in mice. J Pharmacol Sci 2010, 112(3):290-298.